Tag Archives: FiercePharma

Merck’s Keytruda aces another cancer trial as results dazzle researchers






The News: Hot on the heels of the final presentation at ASCO’s 4-day conference in Chicago, a small, new study is causing jaws to drop after it found that a… Read more »

CAR-T Therapy: Personalized medicine with the promise of a cure; payers will decide who gets it






The News: Swiss drug giant Novartis AG has drawn widespread praise and a rising dose of controversy pertaining to its breakthrough CAR-T therapy CTL019. The medicine is under review to… Read more »

What’s wrong with Novartis? Actually nothing.






The News: Novartis AG (Basel CHE) has been the subject of widespread and lingering chatter to the effect that its stature among the Big Pharma league players has diminished, and… Read more »

Biogen spinoff Bioverativ buys Bristol-Myers’ iPierian spinout True North for $825 million; deal shows how to get several bites at the same assets






The News: Bioverativ Inc. (Waltham MA) announced that it entered into a definitive agreement to acquire True North Therapeutics Inc. (South San Francisco) for up to $825 million, including an… Read more »

Glaxo dodges another Advair punch as second generic attempt crashes; Big Pharma’s plight highlights new world order for competition and innovation






The News: GlaxoSmithKline PLC is likely to escape generic competition to its blockbuster lung drug Advair in the US this year, after a second application for a cut-price equivalent form… Read more »

Pfizer’s mixed 1Q results spur M&A hopes; is Bristol-Myers a “done deal”?






The News: Pfizer Inc. said Tuesday (May 2, 2017) that first-quarter sales declined 2% year-over-year to $12.8 billion, missing analyst estimates of $13.1 billion, with the company highlighting one less… Read more »

OncoMed rocked by combo punch as cancer trial bombs and Bayer walks; CEO not about to raise white flag






The News: OncoMed Pharmaceuticals Inc. (Redwood City CA) began the week with a combination punch that some say spells a knockout in the near future. In back-to-back statements, OncoMed revealed… Read more »

Indy’s Eli Lilly making noise with cancer push; Brickyard neighbor revving its drug-discovery engine






I’ve been to the headquarters of Eli Lilly & Co.–about 15 minutes (or about 5 miles) from the “Brickyard” where the Indianapolis 500 is run each year. The racing is… Read more »

After Trump’s charge of “getting away with murder,” J&J, other Pharmas scramble to tout price restraints; but who’s kidding whom?






Steve’s Take: I thought the pharma business, like any other, was built on the bedrock precept of: charge what the market will bear, until you’re forced to pull back the… Read more »

Valeant CEO tries to paint happy face on 4Q results; markets not buying the turnaround–yet?






The News: Valeant Pharmaceuticals International Inc.’s (Laval Quebec) fourth-quarter loss widened to $515 million versus $385 million in the same period of 2015, as sales plummeted 13% year-over-year to $2.4… Read more »